Valuing vaccination

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12313-12319

  Bärnighausen, Till ^a,b   Bloom, David E ^a   Cafiero Fonseca, Elizabeth T ^a   O'Brien, Jennifer Carroll ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Benefit cost analysis; Immunization

Indexed keywords

VACCINE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; SYSTEMATIC REVIEW (TOPIC); VACCINATION; ECONOMICS; EVIDENCE BASED MEDICINE; HERD IMMUNITY; INFECTION CONTROL; SOCIOECONOMICS;

COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, HERD; SOCIOECONOMIC FACTORS; VACCINATION;

EID: 84906691708     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400475111     Document Type: Review

References (75)

1. Levine OS, et al. (2011) The future of immunisation policy, implementation, and financing. Lancet 378(9789):439-448.
2. Centers for Disease Control and Prevention (CDC) (2011) Ten great public health achievements-worldwide, 2001-2010. MMWR Morb Mortal Wkly Rep 60(24):814-818.
3. World Health Organization, UNICEF (2014) Immunization Data: A Statistical Reference Containing Data Through 2012 (World Health Organization, Geneva).
4. World Health Organization, UNICEF, World Bank (2009) State of the World's Vaccines and Immunization (World Health Organization, Geneva), 3rd Ed.
5. World Health Organization (2013) Poliomyelitis, Fact Sheet No114 (World Health Organization, Geneva).
6. World Health Organization (2014) Global Immunization Data; February 2014 (World Health Organization, Geneva).
7. Markowitz LE, et al. (2012) Human papillomavirus vaccine introduction - the first five years. Vaccine 30(Suppl 5):F139-F148.
8. Hopkins TG, Wood N (2013) Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine 31(13):1673-1679.
9. Gandhi G, et al. (2013) Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020. Vaccine 31(Suppl 2):B137-B148.
10. World Health Organization (2013) Sixty-Sixth World Health Assembly WHA66.2. Agenda Item 12.3: Programme Budget 2014-2015 (World Health Organization, Geneva).
11. Bloom DE, Canning D (2000) Policy forum: Public health. The health and wealth of nations. Science 287(5456):1207-1209, 1209.
12. Bloom D, Fink G (2013) The economic case for devoting public resources to health. Manson's Tropical Diseases, eds Farrar J, et al. (Elsevier, New York), 23rd Ed, pp 23-30.
13. Bloom DE, Canning D, Mansfield RK, Moore M (2007) Demographic change, social security systems, and savings. J Monet Econ 54(1):92-114.
14. Alsan M, Bloom DE, Canning D (2006) The effect of population health on foreign direct investment inflows to low- and middle-income countries. World Dev 34(4):613-630.
15. Bloom DE (2011) 7 billion and counting. Science 333(6042):562-569.
16. Colgrove J (2006) Diphtheria immunization: The power, and the limits, of persuasion. State of Immunity: The Politics of Vaccination in Twentieth-Century America (Univ of California Press, Berkeley), pp 81-112.
17. Lydon P, Gandhi G, Vandelaer J, Okwo-Bele JM (2014) Health system cost of delivering routine vaccination in low- and lower-middle income countries: What is needed over the next decade? Bull World Health Organ 92(5):382-384.
18. Bärnighausen T, et al. (2011) Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine 29(13):2371-2380.
19. Bärnighausen T, Bloom DE, Canning D, O'Brien J (2008) Accounting for the full benefits of childhood vaccination in South Africa. S Afr Med J 98(11):842, 844-846.
20. Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC (2013) Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol 25(2):104-113.
21. Bärnighausen T, Bloom DE, Cafiero ET, O'Brien JC (2012) Economic evaluation of vaccination: Capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect 18(Suppl 5):70-76.
22. Heiskanen-Kosma T, Korppi M, Leinonen M (2003) Serologically indicated pneumococcal pneumonia in children: A population-based study in primary care settings. APMIS 111(10):945-950. (Pubitemid 37352612)
23. Goetghebuer T, et al. (2000) Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 5(3):207-213. (Pubitemid 30196234)
24. Chandran A, Herbert H, Misurski D, Santosham M (2011) Long-term sequelae of childhood bacterial meningitis: An underappreciated problem. Pediatr Infect Dis J 30(1):3-6.
25. Grimwood K, Anderson P, Anderson V, Tan L, Nolan T (2000) Twelve year outcomes following bacterial meningitis: Further evidence for persisting effects. Arch Dis Child 83(2):111-116. (Pubitemid 30670418)
26. Tuomanen EI (2000) Pathogenesis of pneumococcal inflammation: Otitis media. Vaccine 19(Suppl 1):S38-S40.
27. Semba RD, Bloem MW (2004) Measles blindness. Surv Ophthalmol 49(2):243-255. (Pubitemid 38304875)
28. Gilbert C, Muhit M (2008) Twenty years of childhood blindness: What have we learnt? Community Eye Health 21(67):46-47.
29. Centers for Disease Control and Prevention (2013) Vaccine-Preventable Adult Diseases (Centers for Disease Control and Prevention, Atlanta).
30. Centers for Disease Control and Prevention (2012) Epidemiology and Prevention of Vaccine-Preventable Diseases, eds Atkinson W, Wolfe C, Hamborsky J (Public Health Foundation, Washington, DC).
31. Canning D, et al. (2011) The effect of maternal tetanus immunization on children's schooling attainment in Matlab, Bangladesh: Follow-up of a randomized trial. Soc Sci Med 72(9):1429-1436.
32. Dewey KG, Begum K (2011) Long-term consequences of stunting in early life. Matern Child Nutr 7(Suppl 3):5-18.
33. Bloom DE, Canning D, Shenoy ES (2012) The effect of vaccination on children's physical and cognitive development in the Phillippines. Appl Econ 44(21):2777-2783.
34. García G, et al. (2011) Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis 15(1):e38-e43.
35. Teele DW, Klein JO, Chase C, Menyuk P, Rosner BA; Greater Boston Otitis Media Study Group (1990) Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years. J Infect Dis 162(3):685-694. (Pubitemid 20266160)
36. Arrossi S, et al. (2007) The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecol Oncol 105(2):335-340. (Pubitemid 46590325)
37. Driessen J (2011) The impact of health interventions on fertility and education: New evidence. PhD thesis (Johns Hopkins Univ, Baltimore).
38. Bloom DE, Canning D, Fink G, Finlay JE (2009) Fertility, female labor force participation, and the demographic dividend. J Econ Growth 14(2):79-101.
39. John TJ, Samuel R (2000) Herd immunity and herd effect: New insights and definitions. Eur J Epidemiol 16(7):601-606.
40. Ward CJ (2014) Influenza vaccination campaigns: Is an ounce of prevention worth a pound of cure? Am Econ J Appl Econ 6(1):38-72.
41. Garland SM, Skinner SR, Brotherton JM (2011) Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Prev Med 53(Suppl 1):S29-S35.
42. Klugman KP (2014) Herd protection induced by pneumococcal conjugate vaccine. Lancet Global Health 2(7):e365-e366.
43. Hammitt LL, et al. (2014) Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: Findings from cross-sectional carriage studies. Lancet Global Health 2(7):e397-e405.
44. Lim GH, et al. (2013) Have changing pneumococcal vaccination programmes impacted disease in Ontario? Vaccine 31(24):2680-2685.
45. Hviid A, Melbye M (2004) Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 22(3-4):378-382. (Pubitemid 37510268)
46. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB (2006) Cost-effectiveness of pneumococcal conjugate vaccine: Evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25(6):494-501. (Pubitemid 43863358)
47. Adam HJ, et al. (2010) Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 28(24):4073-4078.
48. Saha SK, et al. (2008) Direct detection of the multidrug resistance genome of Haemophilus influenzae in cerebrospinal fluid of children: Implications for treatment of meningitis. Pediatr Infect Dis J 27(1):49-53.
49. Kyaw MH, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354(14):1455-1463.
50. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M (2012) Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health 12:878.
51. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS (2012) Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine 31(1):96-108.
52. Verguet S, et al. (2013) Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine 31(42):4902-4910.
53. Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC (2013) Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine 31(46):5430-5434.
54. Stack ML, et al. (2011) Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity. Health Aff (Millwood) 30(6):1021-1028.
55. Bloom DE, Canning D, Weston M (2005) The value of vaccination. World Econ 6(3):15-39.
56. Shin S, Shin YJ, Ki M (2008) Cost-benefit analysis of haemophilus influenzae type B immunization in Korea. J Korean Med Sci 23(2):176-184.
57. Anekwe TD (2011) Childhood vaccination and human capital outcomes in South Africa and India. SD thesis (Harvard School of Public Health, Boston).
58. Seet RC, Quek AM, Lim EC (2007) Post-infectious fatigue syndrome in dengue infection. J Clin Virol 38(1):1-6. (Pubitemid 44881429)
59. Teixeira LdeA, et al. (2010) [Persistence of dengue symptoms in patients in Uberaba, Minas Gerais State, Brazil]. Cad Saude Publica 26(3):624-630.
60. Institute of Medicine, National Research Council (2014) Considerations in Applying Benefit-Cost Analysis to Preventive Interventions for Children, Youth, and Families: Workshop Summary (National Academies Press, Washington, DC).
61. Hoddinott J, Maluccio JA, Behrman JR, Flores R, Martorell R (2008) Effect of a nutrition intervention during early childhood on economic productivity in Guatemalan adults. Lancet 371(9610):411-416. (Pubitemid 351173322)
62. Lopez Boo F, Palloni G, Urzua S (2014) Cost-benefit analysis of a micronutrient supplementation and early childhood stimulation program in Nicaragua. Ann N Y Acad Sci 1308(1308):139-148.
63. Miller M, Fumia D, Kay N, Lee S, Aos S (2014) Inventory of Evidence-Based, Research-Based, and Promising Practices: Prevention and Intervention Services for Adult Behavioral Health Benefit-Cost and Meta-Analysis Results (Washington State Institute for Public Policy, Olympia, WA).
64. Psacharopoulos G, Patrinos HA (2004) Returns to investment in education: A further update. Educ Econ 12(2):113-134.
65. Behrman JR, Stacey N (1997) The Social Benefits of Education (Univ of Michigan Press, Ann Arbor, MI).
66. Haveman RH, Wolfe BL (1984) Schooling and economic well-being: The role of nonmarket effects. J Hum Resour 19(3):377-407.
67. Roberts RR, Mensah EK, Weinstein RA (2010) A guide to interpreting economic studies in infectious diseases. Clin Microbiol Infect 16(12):1713-1720.
68. Keith JA, Agostini Bigger L, Arthur PA, Maes E, Daems R (2013) Delivering the promise of the decade of vaccines: Opportunities and challenges in the development of high quality new vaccines. Vaccine 31(Suppl 2):B184-B193.
69. Kremer M (2004) Making vaccines pay. Milken Institute Rev 2004:42-53.
70. Grabowski H (2005) Encouraging the development of new vaccines. Health Aff (Millwood) 24(3):697-700.
71. Batson A, Meheus F, Brooke S (2006) Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 24, Supplement 3(0):S219-S225. (Pubitemid 44293020)
72. Bärnighausen T, et al. (2014) Reassessing the value of vaccines. Lancet Glob Health 2(5):e251-e252.
73. Folha de S.Paulo (2008) Dengue faz Turismo Cair Até 30% no Rio, Diz Associação (Folha Online).
74. Clarin.com (2008) La Epidemia de Dengue en Brasil está Fuera de Control y ya Afecta al Turismo.
75. Capeding MR, et al. (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet, 10.1016/S0140-6736(14)61060- 6.